VivoSeq
Oncology

Langerhans Cell Histiocytosis

32

Pipeline Programs↗

9

Active Trials↗

19

Companies Involved↗

Langerhans Cell Histiocytosis is a moderately active landscape with 32 programs across 19 companies. The most active players are Novartis, Genzyme, a Sanofi Company, GSK. 4 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

67/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 2G

Genzyme, a Sanofi Company

2 programs

Phase 2GSK logo

GSK

1 program

Phase 2Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

1 program

Phase 2Day One Biopharmaceuticals logo

Day One Biopharmaceuticals

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

32 of 36 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%Cell therapy13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 100% of 36 pipeline programs.

Analysis

Trial Status

20

clinical trials

Recruiting7 · 35%
Unknown status5 · 25%
Completed4 · 20%
Terminated1 · 5%
Enrolling by invitation1 · 5%
Withdrawn1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

20 trials

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Recruiting·WWest China Second University Hospital·N/A·NCT07431060·120 enrolled
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
Recruiting·WWest China Second University Hospital·Phase 2·NCT07022834·20 enrolled
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Recruiting·—·Phase 3·NCT02670707·124 enrolled
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05828069·48 enrolled
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Recruiting·CCook Children's Health Care System·Phase 2·NCT06582745·75 enrolled
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Recruiting·—·Phase 2·NCT04079179·90 enrolled
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Recruiting·NNorth American Consortium for Histiocytosis·Phase 2/3·NCT02205762·1,400 enrolled
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT02425904·25 enrolled
Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
Enrolling by invitation·SSecond Affiliated Hospital of Wenzhou Medical University·Phase 1·NCT06902792·6 enrolled
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
Completed·—·Phase 2·NCT00048373·20 enrolled
Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
Completed·HHistiocyte Society·N/A·NCT00276757·376 enrolled
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
Completed·GSK logoGSK·Phase 2·NCT01395004·17 enrolled
Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis
Completed·PPeking Union Medical College Hospital·Phase 2·NCT02389400·43 enrolled
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00618540·1 enrolled
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
Withdrawn·UUniversity of New Mexico·Phase 3·NCT00488605
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)